We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ranbaxy, Teva to Share Exclusivity on Generics of Eisai’s Aricept
Ranbaxy, Teva to Share Exclusivity on Generics of Eisai’s Aricept
December 7, 2010
Ranbaxy Laboratories and Teva Pharmaceutical Industries have won FDA approval to market generic versions of Eisai’s blockbuster Alzheimer’s drug Aricept and will share 180-day exclusivity on the drug.